Sugi Predict

Sugi Predict / Targets / EIF3F

EIF3F

Eukaryotic translation initiation factor 3 subunit F · O00303 · EIF3F on Sugi Atlas →

21 patent compounds predicted against EIF3F, 17 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21943538 SCHEMBL21943538 0.59 1/20
SCHEMBL21943762 SCHEMBL21943762 0.57 1/20
SCHEMBL21944043 SCHEMBL21944043 0.55 1/20
SCHEMBL21943004 SCHEMBL21943004 0.55 1/20
SCHEMBL21942995 SCHEMBL21942995 0.53 1/20
SCHEMBL21943411 SCHEMBL21943411 0.53 1/20
SCHEMBL14042267 SCHEMBL14042267 0.52 1/20
SCHEMBL21943429 SCHEMBL21943429 0.52 1/20
SCHEMBL22066328 SCHEMBL22066328 0.51 1/20
SCHEMBL21943540 SCHEMBL21943540 0.49 1/20
SCHEMBL21943537 SCHEMBL21943537 0.45 1/20
SCHEMBL24016281 SCHEMBL24016281 0.44 1/20
SCHEMBL24532074 SCHEMBL24532074 0.42 1/20
SCHEMBL1454562 SCHEMBL1454562 0.42 1/20
SCHEMBL17612956 SCHEMBL17612956 0.42 1/20
SCHEMBL12399198 SCHEMBL12399198 0.42 1/20
SCHEMBL29911712 SCHEMBL29911712 0.40 1/20

Clinical trials — most relevant to EIF3F by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Quantification of GADD34 Expression in RA nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib nanCOMPLETED
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure nanUNKNOWN
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
miRNA as a Growth Plate Marker After GH nanUNKNOWN
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EIF3F binder may also engage these)

ProteinNameSimilarity
A5A6I3 — 1.000 A5A6I3 →
Q4R5B8 — 1.000 Q4R5B8 →
Q9DCH4 — 1.000 Q9DCH4 →
Q6ZKM2 — 0.992 Q6ZKM2 →
Q8W1P0 — 0.986 Q8W1P0 →
Q8W206 — 0.981 Q8W206 →
Q0D1J4 — 0.980 Q0D1J4 →
Q9VCY3 — 0.980 Q9VCY3 →
Q0CCM5 — 0.980 Q0CCM5 →
O04202 — 0.979 O04202 →
A1D379 — 0.979 A1D379 →
Q2GZK0 — 0.978 Q2GZK0 →
A6RQZ9 — 0.978 A6RQZ9 →
Q1DRC9 — 0.977 Q1DRC9 →
Q2UPM0 — 0.977 Q2UPM0 →
Q7S9Y9 — 0.977 Q7S9Y9 →
B0XQ55 — 0.976 B0XQ55 →
A7E7B3 — 0.976 A7E7B3 →
Q4WTH0 — 0.976 Q4WTH0 →
Q2U2J1 — 0.976 Q2U2J1 →
A2QQA2 — 0.975 A2QQA2 →
B0XQB9 — 0.974 B0XQB9 →
Q0UTQ6 — 0.974 Q0UTQ6 →
Q4WTA6 — 0.974 Q4WTA6 →
Q6AXJ2 — 0.974 Q6AXJ2 →
A1D3E1 — 0.974 A1D3E1 →
A1CQB4 — 0.974 A1CQB4 →
A1CQH7 — 0.973 A1CQH7 →
A2QQ10 — 0.973 A2QQ10 →
Q0UMR2 — 0.973 Q0UMR2 →